复星医药子公司注射用乳糖酸红霉素注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable lactulose red mycin accepted by the National Medical Products Administration, aimed at treating infections caused by specific microbial sensitive strains, preventing initial rheumatic fever, preventing recurrence of rheumatic fever, and preventing bacterial endocarditis [1] Group 1 - The drug registration application was accepted by the National Medical Products Administration [1] - The drug is intended for multiple therapeutic uses, including treatment of infections and prevention of rheumatic fever and bacterial endocarditis [1]